Skip to main content
SpringerLink
Log in

GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors

  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

Abstract

Glucagon-like peptide-1 (GLP-1)-based therapy is a novel treatment for type 2 diabetes. It is executed either by GLP-1 mimetics or by dipeptidyl peptidase-IV inhibitors. In type 2 diabetes, the two strategies reduce hemoglobin A1c by 0.6% to 1.1% from baseline levels of 7.7% to 8.5%. They are efficient both in monotherapy and in combination with metformin or thiazolidinediones. Both treatments are well tolerated with low risk of hypoglycemia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Drucker DJ, Nauck MA: The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696–1705.

    Article  PubMed  CAS  Google Scholar 

  2. Dunning BE, Foley J, Ahrén B: Alpha-cell function in health and disease: influence of GLP-1. Diabetologia 2005, 48:1700–1713.

    Article  PubMed  CAS  Google Scholar 

  3. Nauck MA, Niedereichholz U, Ettler R, et al.: Glucagonlike peptide-1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 1997, 6:E981–E988.

    Google Scholar 

  4. Gutzwiller JP, Drewe J, Böke B, et al.: Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 1999, 276:R1541–R1544.

    PubMed  CAS  Google Scholar 

  5. Perfetti R, Hui H: The role of GLP-1 in the life and death of pancreatic beta cells. Horm Metab Res 2004, 36:804–810.

    Article  PubMed  CAS  Google Scholar 

  6. Ahrén B, Schmitz O: GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res 2004, 36:867–887.

    Article  PubMed  CAS  Google Scholar 

  7. Meier JJ, Nauck MA: GIP as a potential therapeutic agent? Horm Metab Res 2004, 36:859–866.

    Article  PubMed  CAS  Google Scholar 

  8. Gutniak M, Ørskov C, Holst JJ, et al.: Antidiabetic effect of glucagon-like peptide-1 (7–36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med 1992, 326:1316–1322.

    Article  PubMed  CAS  Google Scholar 

  9. Zander M, Madsbad S, Madsen JL, Holst JJ: Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002, 359:824–830.

    Article  PubMed  CAS  Google Scholar 

  10. Mentlein R: Dipeptidyl-peptidase IV (CD26)—role in the inactivation of regulatory peptides. Regul Pept 1999, 85:9–24.

    Article  PubMed  CAS  Google Scholar 

  11. Knudsen LB, Kiel D, Teng M, et al.: Small-molecule agonists for the glucagon-like peptide 1 receptor. Proc Natl Acad Sci U S A 2007, 104:937–942.

    Article  PubMed  CAS  Google Scholar 

  12. Ahrén B: Exenatide: a novel treatment of type 2 diabetes. Therapy 2005, 2:207–222.

    Article  Google Scholar 

  13. Koltermann OG, Buse JB, Fineman MS, et al.: Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003, 88:3082–3089.

    Article  CAS  Google Scholar 

  14. Buse JB, Henry RR, Han J, et al.: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004, 27:2628–2635.

    Article  PubMed  CAS  Google Scholar 

  15. DeFronzo RA, Ratner RE, Han J, et al.: Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005, 28:1092–1100.

    Article  PubMed  CAS  Google Scholar 

  16. Kendall DM, Riddle MC, Rosenstock J, et al.: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005, 28:1083–1091.

    Article  PubMed  CAS  Google Scholar 

  17. Ratner RE, Maggs D, Nielsen LL, et al.: Long-term effects of exenatide therapy over 82 weeks on glycemic control and weight in over-weight metformin-treated patients with type 2 diabetes. Diabetes Obes Metab 2006, 8:419–428.

    Article  PubMed  CAS  Google Scholar 

  18. Heine RJ, Can Gaal LF, Johns D, et al.: Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005, 43:559–569.

    Google Scholar 

  19. Nauck MA, Duran S, Kim D, et al.: A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulphonylurea and metformin: a non-inferiority study. Diabetologia 2007, 50:259–267.

    Article  PubMed  CAS  Google Scholar 

  20. Fineman MS, Shen LZ, Taylor K, et al.: Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes Metab Res Rev 2004, 20:411–417.

    Article  PubMed  CAS  Google Scholar 

  21. Knudsen LB, Agerso H, Bjenning C, et al.: GLP-1 derivatives as novel compounds for the treatment of type 2 diabetes: selection of NN2211 for clinical development. Drugs Future 2001, 26:677–685.

    Article  CAS  Google Scholar 

  22. Vilsbøll T: Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus. Expert Opin Investig Drugs 2007, 16:231–237.

    Article  PubMed  Google Scholar 

  23. Madsbad S, Schmitz O, Ranstam J, et al.: Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomised, controlled trial. Diabetes Care 2004, 27:1335–1342

    Article  PubMed  CAS  Google Scholar 

  24. Vilsbøll T, Zdravkovic M, Le-Thi T, et al.: Liraglutide, a long-acting human GLP-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycaemia in patients with type 2 diabetes mellitus. Diabetes Care 2007, 30:1608–1610.

    Article  PubMed  CAS  Google Scholar 

  25. Nauck MA, Hompesch M, Filiupczak R, et al.: Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes 2006, 114:417–423.

    Article  PubMed  CAS  Google Scholar 

  26. Feinglos MN, Saad MF, Pi-Sunyer FX, et al.: Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with type 2 diabetes. Diabet Med 2005, 22:1016–1023.

    Article  PubMed  CAS  Google Scholar 

  27. Holst JJ, Deacon CF: Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 1998, 47:1663–1670.

    Article  PubMed  CAS  Google Scholar 

  28. Ahrén B, Simonsson E, Larsson H, et al.: Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4 week study period in type 2 diabetes. Diabetes Care 2002, 25:869–875.

    Article  PubMed  Google Scholar 

  29. Kim D, Wang L, Beconi M, et al.: (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazol[4,3,a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005, 48:141–151.

    Article  PubMed  CAS  Google Scholar 

  30. Ahrén B: Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties. Exp Opin Invest Drugs 2006, 15:431–442.

    Article  CAS  Google Scholar 

  31. Ahrén B, Landin-Olsson M, Jansson PA, et al.: Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004, 89:2078–2084.

    Article  PubMed  CAS  Google Scholar 

  32. Ristic S, Byiers S, Foley J, Holmes D: Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabet Obes Metab 2005, 7:692–698.

    Article  CAS  Google Scholar 

  33. Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D: Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 2006, 387:423–438.

    Article  CAS  Google Scholar 

  34. Rosenstock J, Baron MA, Camisasca RP, et al.: Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2007, 9:175–185.

    Article  PubMed  CAS  Google Scholar 

  35. Dejager S, Lebeaut A, Couturier A, Schweizer A: Sustained reduction in HbA1c during one-year treatment with vildagliptin in patients with type 2 diabetes (T2DM). Diabetes 2006, 55(suppl 1):A29.

    Google Scholar 

  36. Scott R, Wu M, Sanchez M, Stein P: Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 2007, 61:171–180.

    Article  PubMed  CAS  Google Scholar 

  37. Hanefeld M, Herman G, Mickel C, et al.: Effect of MK-0431, a dipeptidyl peptidase IV (DPP-IV) inhibitor, on glycemic control after 12 weeks in patients with type 2 diabetes. Diabetelogia 2005, 49(suppl 1):A287.

    Google Scholar 

  38. Raz I, Hanefeld M, Xu L, et al.: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006, 49:2564–2571.

    Article  PubMed  CAS  Google Scholar 

  39. Aschner P, Kipnes MS, Lunceford JK, et al.: Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006, 29:2632–2637.

    Article  PubMed  CAS  Google Scholar 

  40. Ahrén B, Gomis R, Standl E, et al.: Twelve-and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004, 27:2874–2880.

    Article  PubMed  Google Scholar 

  41. Bosi E, Camisaca RP, Collober C, et al.: Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007, 30:890–895.

    Article  PubMed  CAS  Google Scholar 

  42. Garber AJ, Schweizer A, Baron MA, et al.: Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 2007, 9:166–174.

    Article  PubMed  CAS  Google Scholar 

  43. Fonseca V, Schweizer A, Albrecht D, et al.: Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007, 50:1148–1155.

    Article  PubMed  CAS  Google Scholar 

  44. Charbonnel B, Karasik A, Liu J, et al.: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006, 29:2638–2643.

    Article  PubMed  CAS  Google Scholar 

  45. Jago C: American Diabetes Association—66th scientific sessions. 9–13 June 2006, Washington, DC, USA, IDrugs 2006, 9:538–541.

    PubMed  Google Scholar 

  46. Rosenstock J, Brazg R, Andryuk PJ, et al.: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006, 28:1556–1568.

    Article  PubMed  CAS  Google Scholar 

  47. Ionut V, Liberty IF, Hucking K, et al.: Exogenously imposed postprandial-like rises in systemic glucose and GLP-1 do not produce an incretin effect, suggesting an indirect mechanism of GLP-1 action. Am J Physiol 2006, 291:E779–E785.

    CAS  Google Scholar 

  48. Hansotia T, Baggio LL, Delmeire D, et al.: Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes 2004, 53:1326–1335.

    Article  PubMed  CAS  Google Scholar 

  49. Mari A, Sallas WM, He YL, et al.: Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005, 90:4888–4894.

    Article  PubMed  CAS  Google Scholar 

  50. Mari A, Nielsen LL, Nanayakkara N, et al.: Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea. Horm Metab Res 2006, 38:838–844.

    Article  PubMed  CAS  Google Scholar 

  51. Chang AM, Jakobsen G, Sturis J, et al.: The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 2003, 52:1786–1791.

    Article  PubMed  CAS  Google Scholar 

  52. Balas B, Baig MR, Watson C, et al.: The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab 2007, 92:1249–1255.

    Article  PubMed  CAS  Google Scholar 

  53. Vella A, Bock G, Giesler PD, et al.: Effects of dipeptidyl peptidase 4 inhibition on gastrointestinal function, meal appearance and glucose metabolism in type 2 diabetes. Diabetes 2007, 56:1475–1480.

    Article  PubMed  CAS  Google Scholar 

  54. Matikainen N, Mänttäri S, Schweizer A, et al.: Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 2006, 49:2049–2057.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Sciences, Division of Medicine, Lund University, B11 BMC, SE-221 84, Lund, Sweden

    Bo Ahrén

Authors
  1. Bo Ahrén
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bo Ahrén.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ahrén, B. GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors. Curr Diab Rep 7, 340–347 (2007). https://doi.org/10.1007/s11892-007-0056-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11892-007-0056-9

Keywords

Search

Navigation